Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised

Richard Gray*, Natalie Ives, Caroline Rick, Smitaa Patel, Alastair Gray, Crispin Jenkinson, Emma McIntosh, Keith Wheatley, Adrian Williams, Carl E. Clarke, P. Sandercock, C. Baigent, P. Crome, A. Williams, R. Abbott, M. Baker, B. Castleton, C. E. Clarke, C. Counsell, A. K. DebS. Fairweather, R. Fitzpatrick, A. Gray, N. Ives, C. Jenkinson, G. MacPhee, T. Malone, D. Mant, E. McIntosh, A. Ming, P. Morrish, P. Ohri, V. Pearce, B. Wood, P. Worth, P. Au, T. Boodell, V. Cheed, C. E. Clarke, J. Daniels, F. Dowling, A. Edmondson, L. Caie, R. Caslake, C. Counsell, P. Crowley, J. Gordon, C. Harris, M. A. Macleod, K. Taylor, PD MED Collaborative Group

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

237 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised'. Together they form a unique fingerprint.

Medicine & Life Sciences